Skip to main content
OpenTrials
Completed

NCT Number: NCT02361736

Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients During Orthopaedic Surgery

Hydroxyethyl starch (HES) is commonly used as plasma expander during surgery but may be nephrotoxic as seen in studies in patients with sepsis. The investigators hypothesized that the possible nephrotoxicity of 6% HES 130/0.4 could be revealed by measurements of urinary and plasma neutrophil gelatinase-associated lipocalin and interleukin-18 (IL-18) in old patients with normal renal function during orthopaedic surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China

About this study

Hydroxyethyl starch (HES) is widely used as volume expander to maintain circulation in patients during surgery, trauma, and in critical disease, where a rapid and sustained volume expansion is the goal. However, acute kidney injury (AKI) is sometimes a complication in these patients and HES might be a contributing factor. Acute kidney injury is often diagnosed using a sudden rise in plasma creatinine (p-crea) or an abrupt decrease in urine output. P-crea depends on sex, nutrition, medication,muscle mass, and age and it increases 24 to 48 h after renal injury, so the diagnosis of AKI is delayed when using p-crea alone as an indicator for renal damage. New technology allows for earlier diagnosis of AKI using measurements of biomarkers in urine. Neutrophil gelatinase-associated lipocalin (NGAL) is a small protein, which is filtered via the glomeruli and reabsorbed in the proximal tubules, and thus low concentrations of NGAL can be measured in the blood and urine. Approximately 6 h after a renal injury, NGAL increases rapidly due to an up-regulated expression and secretion in the epithelial cells of the thick ascending limb of Henle's loop, the distal tubules, and the collecting ducts. Thus, NGAL can be used as a marker of renal damage. However, infections and malignancies can give falsely increased levels.

Interleukin-18 (IL-18) is mainly created from proximal kidney tubules which is a proinflammatory factor that can be detected in earlier urine of AKI animal models. There is significant rise in IL-18 levels in urine of AKI confirmed cases(no chronic kidney disease, no urinary tract infections, no prerenal factors), specificity and susceptibility is 90%. As a result, IL-18 can be selected as a biomarker.

Intravenously administrated HES is excreted in urine but is also partly accumulated in the tissues. Studies in animals and humans showed that HES molecules were accumulated in the proximal tubule cells with subsequent vacuolization and swelling-a condition known as osmotic nephrosis. However, recent studies, primarily conducted in patients with sepsis, found impaired renal function even when using tetrastarch. In contrast, perioperative studies found no evidence of AKI after infusion of HES. The investigators hypothesized that 6% HES 130/0.4 had a nephrotoxic effect, which could be revealed by measurements of urinary and plasma NGAL and IL-18; that 6% HES 130/0.4 influenced kidney function differently than crystalloids(lactated Ringer's solution) due to the different pharmacokinetic properties of colloids compared with that of crystalloids.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Old patients scheduled to undergo orthopaedic surgery under a intravertebral anesthesia. (American Society of Anesthesiologists physical status I-Ⅲ)

Exclusion criteria

  • Allergy and contraindication to HES
  • Infections and malignancies
  • Sepsis
  • History of heart failure or New York Heart Association(NYHA)>Ⅲ
  • Renal failure or Cr>108μmol/L,BUN>8.3mmol/L
  • Undergoing dialytic treatments
  • Intracranial hemorrhages
  • Taking non-steroidal antiinflammatory agent for a long time
  • Inability to understand the Study Information Sheet and provide a written consent to take part in the study

Treatment and study plan

Hydroxyethyl starch

Drug

6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery

Other names: HES

Lactate Ringers

Drug

Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery

Other names: LR

Primary outcomes

  1. Concentration of NGAL in Urine on 5 Time Point

    Time frame: -1d, 0d, 1d, 3d, 5d after surgery

    Neutrophil gelatinase-associated lipocalin (NGAL) is a small protein, which is filtered via the glomeruli and reabsorbed in the proximal tubules, and thus low concentrations of NGAL can be measured in the blood and urine.

  2. Concentration of IL-18 in Urine on 5 Time Point

    Time frame: -1d, 0d, 1d, 3d, 5d after surgery

    IL-18 is mainly created from proximal kidney tubules which is a proinflammatory factor that can be detected in earlier urine of AKI animal models.

  3. Concentration of IL-18 in Plasma on 5 Time Point

    Time frame: -1d, 0d, 1d, 3d, 5d after surgery

  4. Concentration of NGAL in Plasma on 5 Time Point.

    Time frame: -1d, 0d, 1d, 3d, 5d after surgery

    concentration of NGAL in plasma on 5 time point. Biomarkers are measured by ELISA.

Secondary outcomes

  1. Concentration of β2 Microglobulin in Urine

    Time frame: -1d, 0d, 1d, 3d, 5d after surgery

  2. Estimated Glomerular Filtration Rate(eGFR) on 5 Time Point

    Time frame: -1d, 0d, 1d, 3d, 5d after surgery

    eGFR is calculated by concentration of creatinine and CKD-EPI2009

  3. Ratio of the Urine Trace Albumin and Creatinine(ACR) on 5 Time Point

    Time frame: -1d, 0d, 1d, 3d, 5d after surgery

    ACR is calculated by the urine trace albumin divided by the urine creatinine

Sponsors and collaborators

Lead sponsor

Yuanyuan Zhang

Other

Collaborators

  • Tianjin First Central Hospital
  • Tianjin Union Medical Center

Registry information

Official study title

Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients

Important dates

Study start
2015
Primary completion
2015
Study completion
2016
First posted
Feb 12, 2015
Registry last updated
Mar 24, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.